S100P is highly expressed in various solid tumors and associated with poor prognosis in CRC (51, 52), breast cancer (53), pancreatic cancer (54), cholangiocarcinoma (55) lung cancer (56), and ovarian cancer (57). Here, S100P is linked to cholangiocarcinoma.